

# UC San Diego

## UC San Diego Previously Published Works

### Title

(-)-5-Demethoxygrandisin B a New Lignan from *Virola surinamensis* (Rol.) Warb. Leaves: Evaluation of the Leishmanicidal Activity by In Vitro and In Silico Approaches.

### Permalink

<https://escholarship.org/uc/item/71z4953f>

### Journal

Pharmaceutics, 15(9)

### ISSN

1999-4923

### Authors

Paes, Steven

Silva-Silva, João

Portal Gomes, Paulo

et al.

### Publication Date

2023-09-07

### DOI

10.3390/pharmaceutics15092292





### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

## Article

# (-)-5-Demethoxygrandisin B a New Lignan from *Viola surinamensis* (Rol.) Warb. Leaves: Evaluation of the Leishmanicidal Activity by In Vitro and In Silico Approaches

Steven Souza Paes <sup>1,†</sup>, João Victor Silva-Silva <sup>2,3,†</sup>, Paulo Wender Portal Gomes <sup>4</sup>, Luely Oliveira da Silva <sup>5</sup>, Ana Paula Lima da Costa <sup>1</sup>, Manoel Leão Lopes Júnior <sup>1</sup>, Daiana de Jesus Hardoim <sup>2</sup>, Carla J. Moragas-Tellis <sup>6</sup>, Noemi Nosomi Taniwaki <sup>7</sup>, Alvaro Luiz Bertho <sup>8,9</sup>, Fábio Alberto de Molfetta <sup>10</sup>, Fernando Almeida-Souza <sup>2,11,\*</sup>, Lourivaldo Silva Santos <sup>1,\*</sup> and Kátia da Silva Calabrese <sup>2</sup>

<sup>1</sup> Institute of Exact and Natural Sciences, Federal University of Pará, Belém 66075-110, PA, Brazil

<sup>2</sup> Laboratory of Protozoology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21041-250, RJ, Brazil; calabrese@ioc.fiocruz.br (K.d.S.C.)

<sup>3</sup> Laboratory of Medicinal and Computational Chemistry, Institute of Physics of São Carlos, University of São Paulo, São Carlos 13418-900, SP, Brazil

<sup>4</sup> Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92123, USA

<sup>5</sup> Department of Natural Sciences, Pará State University, Belém 66095-015, PA, Brazil

<sup>6</sup> Laboratory of Natural Products for Public Health, Pharmaceutical Technology Institute, Farmanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, RJ, Brazil

<sup>7</sup> Electron Microscopy Nucleus, Adolfo Lutz Institute, São Paulo 01246-000, SP, Brazil

<sup>8</sup> Laboratory of Immunoparasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, RJ, Brazil; alvaro.bertho@ioc.fiocruz.br

<sup>9</sup> Flow Cytometry Core Facility, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, RJ, Brazil

<sup>10</sup> Laboratory of Molecular Modeling, Institute of Exact and Natural Sciences, Federal University of Pará, Belém 66075-110, PA, Brazil; fabioam@ufpa.br

<sup>11</sup> Postgraduate Program in Animal Science, State University of Maranhão, Sao Luis 65055-310, MA, Brazil

\* Correspondence: fernandoalsouza@gmail.com (F.A.-S.); lss@ufpa.br (L.S.S.)

† These authors contributed equally to this work.



**Citation:** Paes, S.S.; Silva-Silva, J.V.; Portal Gomes, P.W.; Silva, L.O.d.; Costa, A.P.L.d.; Lopes Júnior, M.L.; Hardoim, D.d.J.; Moragas-Tellis, C.J.; Taniwaki, N.N.; Bertho, A.L.; et al. (-)-5-Demethoxygrandisin B a New Lignan from *Viola surinamensis* (Rol.) Warb. Leaves: Evaluation of the Leishmanicidal Activity by In Vitro and In Silico Approaches. *Pharmaceutics* **2023**, *15*, 2292. <https://doi.org/10.3390/pharmaceutics15092292>

(-)-5-Demethoxygrandisin B a New Lignan from *Viola surinamensis* (Rol.) Warb. Leaves: Evaluation of the Leishmanicidal Activity by In Vitro and In Silico Approaches.

*Pharmaceutics* **2023**, *15*, 2292.

<https://doi.org/10.3390/pharmaceutics15092292>

Academic Editor: Javier Garcia-Pardo

Received: 21 July 2023

Revised: 17 August 2023

Accepted: 21 August 2023

Published: 7 September 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Leishmaniasis is a complex disease caused by infection with different *Leishmania* parasites. The number of medications used for its treatment is still limited and the discovery of new drugs is a valuable approach. In this context, here we describe the in vitro leishmanicidal activity and the in silico interaction between trypanothione reductase (TryR) and (-)-5-demethoxygrandisin B from the leaves of *Viola surinamensis* (Rol.) Warb. The compound (-)-5-demethoxygrandisin B was isolated from *V. surinamensis* leaves, a plant found in the Brazilian Amazon, and it was characterized as (7R,8S,7'R,8'S)-3,4,5,3',4'-pentamethoxy-7,7'-epoxylignan. In vitro antileishmanial activity was examined against *Leishmania amazonensis*, covering both promastigote and intracellular amastigote phases. Cytotoxicity and nitrite production were gauged using BALB/c peritoneal macrophages. Moreover, transmission electron microscopy was applied to probe ultrastructural alterations, and flow cytometry assessed the shifts in the mitochondrial membrane potential. In silico methods such as molecular docking and molecular dynamics assessed the interaction between the most stable configuration of (-)-5-demethoxygrandisin B and TryR from *L. infantum* (PDB ID 2JK6). As a result, the (-)-5-demethoxygrandisin B was active against promastigote (IC<sub>50</sub> 7.0 μM) and intracellular amastigote (IC<sub>50</sub> 26.04 μM) forms of *L. amazonensis*, with acceptable selectivity indexes. (-)-5-demethoxygrandisin B caused ultrastructural changes in promastigotes, including mitochondrial swelling, altered kDNA patterns, vacuoles, vesicular structures, autophagosomes, and enlarged flagellar pockets. It reduced the mitochondria membrane potential and formed bonds with important residues in the TryR enzyme. The molecular dynamics simulations showed stability and favorable interaction with TryR. The compound targets *L. amazonensis* mitochondria via TryR enzyme inhibition.

**Keywords:** *Leishmania amazonensis*; mitochondrial membrane potential; flow cytometry; trypanothione reductase; computational studies

## 1. Introduction

Herbal preparations are plant-based and are often used for the treatment of many diseases. For instance, species from the Myristicaceae family are used by indigenous people of the Amazon region as a source of powerfully hallucinogenic narcotics, triggering chemical and pharmacological interest in the species of this family during the 1950s [1]. Belonging to the Myristicaceae family, *Virola surinamensis* is among the best-known *Virola* species and is popularly known as ucuúba, ucuúba-branca, ucuúba-cheirosa, ucuúba-de-igapó, ucuúba-da-várzea, ucuúba-verdadeira, bicuíba, bicuíba-branca, tree-de-tallow, and virola [2].

Lignans and neolignans have been successfully extracted from the leaves of *V. pavoni*, *V. surinamensis*, *V. michelli*, and *V. sebifera* [3–5]. Among these, (-)-5-demethoxygrandisin B arises as a tetrahydrofuran lignan, constituting its first occurrence of isolation within the *Virola* genus. Its structure bears similarity to (-)-5-demethoxygrandisin, another tetrahydrofuran lignan previously isolated from the leaves and tree barks of *V. surinamensis*. The key distinction between (-)-5-demethoxygrandisin and (-)-5-demethoxygrandisin B lies in the configuration of the furan ring. *V. surinamensis* is widely found in Central and South America, including Brazil, and its constituents have been reported with interesting pharmacological properties, such as anti-chagasic, anti-malarial, and leishmanicidal activities [6–11]. Additionally, the leaves and seeds of *V. surinamensis* contain a high content of lignans [12], well-known as a promising class of compounds against *Leishmania* spp. [13].

Leishmaniasis is a complex of diseases caused by infection with different *Leishmania* parasites from the Trypanosomatidae family. It is transmitted through the bite of infected female sandflies, with diverse clinical manifestations such as a cutaneous, mucocutaneous, and visceral diseases in the Old and New World [14]. Leishmaniasis is considered a neglected disease, and it is estimated that more than 1 billion people are at risk of infection because they live in areas endemic to leishmaniasis [15].

Leishmaniasis predominantly impacts communities already facing vulnerability due to factors such as poverty, limited healthcare access, and various adversities. Finding new medicines represents a humanitarian endeavor aimed at enhancing the well-being of these individuals and guaranteeing their access to treatments that are both impactful and accessible. Moreover, its treatment remains a huge challenge due to serious limitations, such as few effective drugs, resistance, toxicity, high cost, and a lack of adherence to the therapeutic protocol [16]. Thus, leishmaniasis remains a major public health problem worldwide.

Among the molecular targets used to search for new drugs against *Leishmania* and *Trypanosoma*, trypanothione reductase (TryR) has been identified as unique to parasites. Also, TryR has been described as an effective target against trypanosomatids. Thus, that enzyme plays a crucial role in the control of redox homeostasis by the parasite, which is vital for its survival in a hostile environment generated by the host as a response to the infection. The TryR has been an interesting binding site for many drug candidates that exhibit inhibitory activities against parasites [17,18].

Therefore, in order to discover new drugs against *Leishmania*, here we describe (-)-5-demethoxygrandisin B as a potential candidate and its behavior to the TryR enzyme.

## 2. Materials and Methods

### 2.1. Botanical Material, Extraction, and Isolation

The species under study was collected by a parataxonomist from Embrapa Amazônia Oriental (1°26'27.5" S 48°26'22.8" W), where an exsiccate from 180,980 was cataloged in the Herbarium. The leaves were dried in an oven at a temperature of 40 °C for a period of two days. After drying, the leaves were crushed and ground in a knife mill,

resulting in 6.2 kg of material. The dried and ground leaves of *V. surinamensis* (4.0 Kg) were sequentially extracted by maceration with hexane (Tedia, Fairfield, CT, USA), ethyl acetate (Tedia, Fairfield, CT, USA), and methanol (Tedia, Fairfield, CT, USA) for a period of seven days for each solvent. The obtained masses of the hexane, EtOAc, and methanol extracts were 61.7 g, 120 g, and 244 g, respectively. EtOAc was selected to exhibit a superior chromatographic profile in thin-layer chromatography. A 6.0 g portion of the EtOAc extract was dissolved in 1 L of MeOH/H<sub>2</sub>O solution (7:3), followed by successive partitioning with 700 mL of hexane (×4) and 700 mL of ethyl acetate (×4). After drying with anhydrous sodium sulfate, both yielded 0.2 g and 2.8 g, respectively. The ethyl acetate phase (2.8 g) was submitted to a fractionation on column chromatography using Silica gel 60 (70–230 mesh) and 230–400 mesh (SILICYCLE, Québec, QC, Canada) as the stationary phase and polarity gradients of acetone in hexane and methanol in acetone, as elution systems. The subfractions were analyzed by thin-layer chromatography (TLC) (silica gel F254, Merck, Darmstadt, Germany) using Hexane/EtOAc (6:4) as the elution system, and ceric sulfate was used as a detection spray. A yellowish oil, obtained in 30% hexane/acetone, was isolated and characterized as the (-)-5-demethoxygrandisin B: (7R,8S,7'R,8'S)-3,4,5,3',4'-pentamethoxy-7,7'-epoxyignan (40 mg). Obtaining the extracts and the substance (-)-5-demethoxygrandisin B is presented in Figure 1.

## 2.2. Spectroscopy of HRMS and NMR for Structural Characterization, and Optic Rotation Determination

The assessment of (-)-5-demethoxygrandisin B at 100 ppm in methanol: H<sub>2</sub>O (80:20) was conducted using a Xevo<sup>®</sup> G2-S QToF coupled with an ACQUITY Ultra Performance LC<sup>™</sup> system (Waters Corp., Milford, MA, USA). The ionization source was configured with a desolvation gas flow (N<sub>2</sub>) at 600 L/h and a desolvation temperature of 150 °C. The cone gas flow (N<sub>2</sub>) was set at 50 L/h, and the source temperature was maintained at 120 °C. Adjustments were made to the capillary and sampling cone voltages, setting them at 1.0 kV and 40 V, respectively. The data acquisition was executed utilizing MassLynx 4.1 software (Waters, Milford, USA) [19,20]. NMR 1D (<sup>1</sup>H and <sup>13</sup>C) and 2D homonuclear-correlated spectroscopy (COSY <sup>1</sup>Hx<sup>1</sup>H), HMBC, and HSQC analyses were acquired with a Bruker 400 spectrometer Ascend<sup>™</sup> (Rheinstetten, Germany) model at 400.15 MHz (<sup>1</sup>H) and 100.62 MHz (<sup>13</sup>C). The chemical shifts were determined relative to CDCl<sub>3</sub> at 0 ppm. A total of 20 mg of (-)-5-demethoxygrandisin B was solubilized in 600 µL of CDCl<sub>3</sub>. TopSpin 3.6.0 software was used for data control and processing. Thereby, the spectra were manually evaluated. The optical rotation of the (-)-5-demethoxygrandisin was measured on a Perkin–Elmer 341 polarimeter (Perkin–Elmer Inc., Waltham, MA, USA).


## 2.3. Ethical Statements and Animals

The implementation of animal procedures adhered to the guidelines established by the National Council for Control of Animal Experimentation (Conselho Nacional de Controle de Experimentação Animal—CONCEA) and received endorsement from the institutional Ethics Committee on Animal Care and Utilization (Comissão de Ética no Uso de Animais do Instituto Oswaldo Cruz—CEUA-IOC L53/2016-A3). Female BALB/c mice aged 4 to 6 weeks were purchased from the Institute of Science and Technology in Biomodels of the Oswaldo Cruz Foundation.

## 2.4. Peritoneal Macrophage Isolation and Parasite Cultures

Thioglycollate-elicited peritoneal macrophages were obtained from BALB/c mice that were injected intraperitoneally 72 h previously with 3 mL of sterile thioglycollate broth as described by Silva-Silva et al. [21]. Then, cells were maintained in RPMI 1640 medium and cultured overnight at 37 °C, under a humidified atmosphere of 5% CO<sub>2</sub>. Promastigotes of *L. amazonensis* H21 (MHOM/BR/76/MA-76) were cultivated at 26 °C in Schneider's Insect medium (Sigma, St Louis, MO, USA). All media were supplemented with 10% fetal

bovine serum (Gibco, Gaithersburg, MD, USA), 100 IU/mL penicillin, and 100 µg/mL streptomycin as previously described [22].



**Figure 1.** Flowchart of obtaining the extracts and (-)-5-demethoxygrandisin B.

### 2.5. Cytotoxicity Assay

To determine the cytotoxic effects of (-)-5-demethoxygrandisin B, the peritoneal macrophages were cultured in 96-well plates ( $5 \times 10^5$  cells/mL) with different concentrations of (-)-5-demethoxygrandisin B (31–994 µM) at least in triplicate up to a final volume of 100 µL per well in 5% CO<sub>2</sub> for 24 h at 37 °C. Wells without cells were used as blanks, and wells with cells and dimethyl sulfoxide (DMSO) 1% were used as controls. All assays were performed in triplicate at three different times using amphotericin B (0.20–27 µM) as the ref-

erence drug. Cell viability was measured using a colorimetric methyl thiazole tetrazolium (MTT) assay [23]. The results were used to calculate the 50% cell cytotoxicity ( $CC_{50}$ ).

#### 2.6. Antileishmanial Activity Assay and Selectivity Index

The promastigote forms of *L. amazonensis* were used at a  $10^6$  parasites/mL concentration from a 3- to 5-day-old culture. The assay was performed in 96-well plates in the presence of different concentrations of (-)-5-demethoxygrandisin B at 16–497  $\mu\text{M}$ , in a final volume of 100  $\mu\text{L}$  per well, and was then incubated for 24 h at 26 °C. Wells with medium and without parasites were used as blanks, and wells with parasites incubated with DMSO 1% were used as controls. Amphotericin B at 0.0169–1  $\mu\text{M}$  was used as the reference drug. The parasite viability post-treatment was ascertained by enumerating live promastigotes, factoring in flagellar motility, employing Neubauer's camera in conjunction with an optical light microscope [24]. This count was compared with the score of the nontreated promastigote growth. The results were expressed as a parasite growth inhibitory concentration of 50% ( $IC_{50}$ ). The effect of (-)-5-demethoxygrandisin B on the intracellular amastigote form was performed in 24-well plates, with coverslips, with peritoneal macrophages ( $5 \times 10^5$  cells per well) cultured and infected with promastigote forms of *L. amazonensis* using a ratio of 10:1 parasite per cell. After 6 h, the cells were washed three times with PBS to remove the free parasites. The infected cells were treated with (-)-5-demethoxygrandisin B at 8–124  $\mu\text{M}$ , or amphotericin B at concentrations spanning 0.169 to 2.7  $\mu\text{M}$ , over a 24 h period. Following this, the coverslips containing the treated and infected cells were fixed using Bouin solution and subsequently stained with Giemsa for subsequent light microscopy analysis. The determination of the  $IC_{50}$  values ensued from quantifying the intracellular amastigotes within 100 host cells, adopting the methodology outlined by Silva-Silva et al. [22]. These experiments were carried out in independent triplicate with each condition performed in triplicate. The selectivity index (SI) was obtained from the ratio of the peritoneal macrophages  $CC_{50}$  and  $IC_{50}$ .

#### 2.7. Nitrite Quantification

The impact of (-)-5-demethoxygrandisin B on nitric oxide (NO) release was assessed indirectly through the quantification of nitrite in the culture supernatants of macrophages ( $5 \times 10^6$  cells/mL) using the Griess reaction. Subsequent to treatment with (-)-5-demethoxygrandisin B (62  $\mu\text{M}$ ) and/or stimulation with *L. amazonensis* ( $3 \times 10^7$  parasites/mL) or LPS (10  $\mu\text{g}/\text{mL}$ ), approximately 50  $\mu\text{L}$  of the supernatants was collected and introduced into designated wells of 96-well plates. To these supernatants, 50  $\mu\text{L}$  of Griess reagent (comprising 25  $\mu\text{L}$  of 1% sulfanilamide in a 2.5%  $\text{H}_3\text{PO}_4$  solution and 25  $\mu\text{L}$  of 0.1% N-(1-naphthyl) ethylenediamine solution) was added. Following a 10 min incubation, the plates were subjected to spectrophotometric analysis at 570 nm, and the nitrite levels were deduced through reference to the standard sodium nitrite curve (ranging from 1.5 to 100  $\mu\text{M}$ ) [21].

#### 2.8. Transmission Electron Microscopy

*L. amazonensis* promastigotes treated with  $IC_{50}$  for (-)-5-demethoxygrandisin B and incubated for 24 h at 26 °C were collected by centrifugation at 5000 rpm for 5 min. The parasites underwent fixation for an overnight duration within a solution comprising 2.5% glutaraldehyde (Sigma, St Louis, MO, USA) immersed in 0.1 M sodium cacodylate buffer (pH 7.2). After this, a sequence of three washes utilizing 0.1 M sodium cacodylate buffer followed. Subsequently, a post-fixation procedure was carried out through immersion in a solution containing 1% osmium tetroxide, 0.8% potassium ferrocyanide, and 5 mM calcium chloride. Following further washing steps in 0.1 M sodium cacodylate buffer, the parasites underwent dehydration through a graduated acetone series before being embedded within EPON 812 resin (Sigma, St Louis, MO, USA). Ultrathin sections, spanning 100 nm, were then attained via Sorvall MT 2-B (Porter Blum) ultramicrotome (Sorvall, Newtown, CT, USA). These sections were subsequently stained with a 5% uranyl acetate aqueous solution and

lead citrate (comprising 1.33% lead nitrate and 1.76% sodium citrate) prior to observation under a transmission electron microscope JEM-1011 (JEOL, Tokyo, Japan) operating at 80 kV [25].

### 2.9. Determination of Mitochondrial Membrane Potential (MMP) ( $\Delta\Psi_m$ )

For the determination of the mitochondrial membrane potential in the promastigote forms of *L. amazonensis*, we used tetramethylrhodamine ethyl ester (TMRE) (Molecular Probes, Carlsbad, CA, USA) and flow cytometry. For this method,  $2 \times 10^6$  parasites/mL were treated with (-)-5-demethoxygrandisin B IC<sub>50</sub> for 24 h at 26 °C. Nontreated parasites were used as a negative control, and heat-killed parasites (60 °C bath for 30 min) were used as a positive control. Post-incubation, the parasites were subjected to centrifugation at  $1500 \times g$  for 5 min at room temperature. Afterward, they were washed with PBS and incubated in a solution of 300  $\mu$ L TMRE (50 nM) in the absence of light for 15 min at room temperature. Subsequently, a flow cytometry analysis was conducted using a CytoFlex flow cytometer (Beckman Coulter Life Sciences, Inc., Brea, CA, USA). TMRE excitation was achieved using a 488 nm blue laser, and the emitted fluorescence was captured with a 585/42 nm bandpass filter. The flow cytometry data were analyzed using CytExpert software version 2.1 (Beckman Coulter Life Sciences, Inc., Brea, CA, USA) [26].

### 2.10. Molecular Docking

The enzyme trypanothione reductase (TryR) is a promising target for the design of new drugs with antileishmanial activity, because it plays a fundamental role in the intracellular redox balance necessary for the survival of parasites of the *Leishmania* genus and is not present in the host system, where it is replaced by its human homologous enzyme (glutathione reductase) [17]. In this sense, the docking calculations were performed using the GOLD program (Genetic Optimization for Ligand Docking) version 5.5 [27] with the crystallographic structure of the TryR enzyme from *L. infantum*, retrieved from the Protein Data Bank (PDB ID 2JK6) with a resolution of 2.95 Å and complexed by the FAD cofactor [28]. GOLD is a docking program that uses the genetic algorithm to explore the conformational flexibility of the ligand in a complex with a partially flexible macromolecule [29]. As the TryR enzyme is a homodimer [30] composed of two identical monomers, the A chain present in the enzyme structure was selected for the docking step, while the B chain was removed in the Chimera program [31]. To perform the docking, the two-dimensional structure of neolignan (-)-5-demethoxygrandisin B was previously constructed in the MarvinSketch program (<https://chemaxon.com/presentation/marvin-the-nextgeneration-of-chemical-drawing>, accessed on 10 July 2020) and later optimized using the molecular mechanic's force field MMFF94 [32] in the Avogadro program [33] for the in silico study of the compound. Subsequently, the GOLD program removed all the water molecules, and hydrogen atoms were added to the TryR enzyme. Then, the binding site was defined based on the location of the residues that participate in the catalytic mechanism (Cys52, Cys57, His461', and Glu466') [34]. Finally, the composite was docked by applying the GoldScore and ChemScore scoring functions with a search efficiency of 100% in GOLD. The GoldScore and ChemScore functions provide rapid results that predict binding affinity with the macromolecule [35]. Because interactions with the amino acid residues of the active site are essential to promote the inhibition of enzyme activity, a visual inspection of the interactions of the more thermodynamically stable conformation of (-)-5-demethoxygrandisin B was performed on the online server PoseView [36,37].

### 2.11. Molecular Dynamics

Initially, the calculation of the electrostatic potential charge for the structure obtained during docking was performed by the Gaussian 03 program [38], applying the restricted electrostatic potential (RESP) [39] combined with the Hartree–Fock method together with the basis (6–31 G(d,p)) [40]. The protonation states of all the amino acid residues present in the enzyme were determined under pH 7.0 by the PROPKA server [41]. The molecular

dynamics (MD) simulations were performed by the AMBER 18 program, implemented by the *pmemd.CUDA* module [42]. The general AMBER force field (GAFF) [43] was used to describe the (-)-5-demethoxygrandisin B ligand, while the MMFF99SB force field was used for the amino acid residues of the enzyme [44]. Using the *tleap* module of the AmberTools18 package, the enzyme–ligand complex was solvated with the TIP3P explicit solvent model in a cubic box with an edge equal to 12 Å, followed by the addition of Cl<sup>-</sup> counterions to neutralize the resulting charges [45]. The system went through 4 energy minimization steps by the SANDER module [46], applying 10,000 steps in the first step with the steepest descent method and 15,000 with the conjugate gradient method, with the following 3 steps being carried out in 10,000 steps evenly split for both methods. Subsequently, the system was gradually heated from 0K to 298K in the NVT set, using the Langevin algorithm [47] with the restriction of the atoms by a force constant equal to 25 kcal/mol·Å<sup>2</sup>. The periodic boundary conditions employed by the Particle Mesh Ewald (PME) method [48] were used to identify long-range electrostatic interactions. The limit condition of 1 atm and the temperature of 298 K were used to maintain constant temperature and pressure set NPT. The SHAKE algorithm [49] was employed to constrain all hydrogen bonds. The equations of motion were integrated every 2 femtoseconds (2 fs) using the Verlet algorithm [50] based on the principle of finite differences. Thus, the enzyme–ligand complex was simulated at a time of 50 ns by the NPT set at a temperature of 298 K. In addition, the CPPTRAJ module [51] available in AMBERTOOLS 18 was applied for a stability analysis, in terms of the root mean square deviation (RMSD) calculation and structural flexibility through the B-factor.

#### Binding Free-Energy Calculations

The molecular mechanics Poisson–Boltzmann surface area (MMPBSA) [52] and molecular mechanics generalized Born surface area (MMGBSA) [53] methods were used to calculate the binding free energy ( $\Delta G_{\text{bind}}$ ) from the complex to the last 10 ns of the MD trajectory, extracted using the CPPTRAJ and MMPBSA.py modules available in AmberTools 18 [54]. Thus, the binding free energy was calculated according to the following equations:

$$\Delta G_{\text{bind}} = \Delta E_{\text{MM}} + \Delta G_{\text{bind,solv}} - T.\Delta S \quad (1)$$

$$\Delta E_{\text{MM}} = \Delta E_{\text{int}} + \Delta E_{\text{ele}} + \Delta E_{\text{vdW}} \quad (2)$$

$$\Delta E_{\text{int}} = \Delta E_{\text{bond}} + \Delta E_{\text{angle}} + \Delta E_{\text{torsion}} \quad (3)$$

$$\Delta G_{\text{bind,solv}} = \Delta G_{\text{GB/PB}} + \Delta G_{\text{n-polar}} \quad (4)$$

$$\Delta G_{\text{n-polar}} = \gamma \times \text{SASA} \quad (5)$$

$$\Delta G_{\text{bind}} = \Delta G_{\text{vdW}} + \Delta G_{\text{ele}} + \Delta G_{\text{GB}} + \Delta G_{\text{n-polar}} \quad (6)$$

The term  $\Delta E_{\text{MM}}$  in Equation (1) represents the molecular mechanical energy;  $\Delta G_{\text{bind,solv}}$  is the free energy of solvation; and the term  $T.\Delta S$  represents the product of the absolute temperature and conformational entropy. In Equation (2), the individual contributions to the mechanical energy are presented, composed of the internal ( $\Delta E_{\text{int}}$ ), electrostatic ( $\Delta E_{\text{ele}}$ ), and van der Waals ( $\Delta E_{\text{vdW}}$ ) energy. The free energy of solvation ( $\Delta G_{\text{bind,solv}}$ ) results from the sum of polar ( $\Delta G_{\text{PB/GB}}$ ) and non-polar ( $\Delta G_{\text{n-polar}}$ ) free energy, as shown in Equation (3). The polar electrostatic contribution was calculated by the Poisson–Boltzmann (PB) and by the generalized Born approximation (GB) methods, while the non-polar energy was estimated by the product between the empirical parameters of the surface tension ( $\gamma$ ) and solvent accessible area (SASA), presented in Equation (4). Finally, the interaction free energy obtained in the last 10 ns of the simulation by the MMGBSA method was decomposed



according to Equation (6), for the analysis of the individual contribution of the amino acid residues. This method has been widely applied in drug design studies due to its satisfactory approach that successfully reproduces experimental results. The main amino acid residues that contribute to the total energy MMGBSA were visualized using the CHEWD plugin, to generate a color-coding model that expresses the magnitude of the contribution by residues [55].

### 2.12. Statistical Analysis

The numerical results were expressed as the mean  $\pm$  standard deviation, and the statistical analyses were conducted through the statistical software GraphPad Prism<sup>®</sup> version 7 (GraphPad Software Inc., San Diego, CA, USA). Differences were considered significant when  $p < 0.05$ .

## 3. Results

### 3.1. Lignan Structure Elucidation

The (-)-5-demethoxygrandisin B (40 mg) was isolated from the ethyl acetate extract and showed yellowish oil characteristics. High-resolution mass spectrometry (HRMS) data provided a molecular formula  $C_{23}H_{30}O_6$  with a calculated and measured precursor monoisotopic mass of 403.2126 Da, corresponding to an error of 0.00 ppm (Supplementary Material Figure S1). After that, it was confirmed by spectroscopic experiments of  $^1H$  and  $^{13}C$  nuclear magnetic resonance (NMR) spectra. The  $^1H$ ,  $^{13}C$ , heteronuclear single-quantum correlation (HSQC), and heteronuclear multiple-bond coherence (HMBC) NMR data are available in Table 1 and in Supplementary Material Figures S2–S6.

**Table 1.**  $^1H$ ,  $^{13}C$ , HSQC, and HMBC NMR data from the (-) 5-demethoxygrandisin B.

No.	$\delta^1_H$ in ppm (CDCl <sub>3</sub> ) (400 MHz)	$\delta^1_C$ in ppm (100 MHz)	HMBC
1	-	137.46	-
2	6.63 (s)	103.14	88.47 (3J)
3	-	153.27	-
4	-	138.12	-
5	-	153.27	-
6	6.63 (s)	103.14	153.27 (2J) 138.12 (3J) 137.87 (3J)
7	4.65 (d, 4.5 Hz)	88.35	-
8	1.80–1.78 (m)	51.06	88.35 (2J)
9	1.09 (d, 6.0 Hz)	14.07/13.83	-
1'	-	134.86	-
2'	6.96 (d, 1.8 Hz)	109.27	148.55 (2J)
3'	-	148.60	-
4'	-	149.14	-
5'	6.85 (d, 8.1 Hz)	110.97	134.86 (3J)
6'	6.92 dd (1.8 and 8.1 Hz)	118.61	109.27 (3J)
7'	4.63 (d, 4.5 Hz)	88.47	-
8'	1.80–1.78 (m)	50.97	88.35 (2J)
9'	1.06 (d, 6.0 Hz)	14.07/13.83	88.47 (3J)
OMe-3/5	3.88 (s)	56.18	153.27 (2J)
OMe-4	3.83 (s)	60.83	138.12 (2J)
OMe-3'	3.87 (s)	55.95	148.60 (2J)
OMe-4'	3.91 (s)	55.95	149.14 (2J)

Multiplicities and coupling constants ( $J$ ) in Hertz are shown in parentheses. HSQC: Heteronuclear Single-Quantum Correlation; HMBC: Heteronuclear Multiple-Bond Coherence; NMR: Nuclear Magnetic Resonance.

The (-)-5-demethoxygrandisin B showed oxybenzyl proton absorptions H-7 and H-7' ( $\delta$  4.65,  $d$ ,  $J = 4.5$  Hz,  $^1H$  and 4.63,  $d$ ,  $J = 4.5$  Hz,  $^1H$ ) and methyl protons H-9 ( $\delta$  1.09,  $d$ ,  $J = 6$  Hz, 3H) and H-9' ( $\delta$  1.06 ( $d$ ,  $J = 6$  Hz, 3H) related to tetrahydrofuran. The presence of oxybenzyl

proton was confirmed by an analysis of the literature on the classes of substances isolated from *V. surinamensis* [11,56]. Based on the  $^1\text{H}$  NMR spectrum, (-)-5-demethoxygrandisin B showed common signals to tetrahydrofuran lignan. This hypothesis was confirmed once signals were observed in the region of aromatic hydrogens at  $\delta_{\text{H}}$  6.96 (*d*,  $J = 1.8$  Hz,  $^1\text{H}$ ), 6.92 (*dd*,  $J = 1.8$  and 8.1 Hz,  $^1\text{H}$ ), and 6.85 (*d*,  $J = 8.1$  Hz,  $^1\text{H}$ ) in an AMX coupling system, assigned to the hydrogens of a 1,3,4-trisubstituted aromatic ring, with the COSY correlation map showing the existing correlations between these signals (Supplementary Material Figures S2–S6).

An analysis of the aromatic hydrogen region of the  $^1\text{H}$  NMR spectrum of the (-)-5-demethoxygrandisin B leads to the conclusion that the two aromatic rings were 3',4'-dimethoxyphenyl and 3,4,5-trimethoxyphenyl. Interpretations of the  $^1\text{H}$  and  $^{13}\text{C}$  NMR, HSQC, and HMBC spectra for (-)-5-demethoxygrandisin B are described in Table 1, where the carbon signals at  $\delta_{\text{C}}$  88.35 and 88.47, as well as those at  $\delta_{\text{C}}$  51.06 and 50.97, were typical, respectively, of carbons C-7, C-7', C-8, and C-8' of tetrahydrofuran lignans [12,57]. Thus, it was possible to infer that the profile of the  $^1\text{H}$  NMR spectrum of (-)-5-demethoxygrandisin B is common to tetrahydrofuran lignan, which has two phenylpropane units linked by an oxygen atom as illustrated in Figure 2. The stereochemistry of the furan ring was identified by analyzing the coupling constants ( $J$ ) with data well-established in the literature presented in the discussion of this paper [9,28,56,58–60].





Figure 2. Chemical structure of the (-)-5-demethoxygrandisin B.

### 3.2. Antileishmanial Activity and Cytotoxicity

In vitro antileishmanial assays were performed to evaluate the effect of the (-)-5-demethoxygrandisin B in the promastigote and intracellular amastigote forms of *L. amazonensis*, as well as its cytotoxic effect against mammal cells. The (-)-5-demethoxygrandisin B exhibited inhibitory activity against both forms in a concentration-dependent manner (Figure 3). (-)-5-demethoxygrandisin B was able to inhibit the promastigote forms of *L. amazonensis* with a 50% inhibitory concentration ( $\text{IC}_{50}$ ) of 7.0  $\mu\text{M}$ . Furthermore, (-)-5-demethoxygrandisin B was active against the intracellular amastigote forms, displaying  $\text{IC}_{50}$  values of 26.04  $\mu\text{M}$ . These results suggest that promastigotes were more sensitive to (-)-5-demethoxygrandisin B treatment. The cytotoxic effect on peritoneal macrophages showed a  $\text{CC}_{50}$  value of 193.37  $\mu\text{M}$ , lower than the values observed for the standard drug amphotericin B. The selectivity index (SI) for promastigotes and intracellular amastigotes showed that (-)-5-demethoxygrandisin B was 26.6 and 7.4 times less toxic for macrophages than parasites, respectively. The reference drug amphotericin B showed antileishmanial activity and cytotoxicity as expected, after 24h of treatment (Table 2).



**Figure 3.** Concentration–response curve of (-)-5-demethoxygrandisin B effects on the viability of *Leishmania amazonensis* promastigote and intracellular amastigote forms. Data represent the mean  $\pm$  standard error of two independent experiments carried out in triplicate.

**Table 2.** IC<sub>50</sub> and CC<sub>50</sub> values ( $\mu$ M) for (-)-5-demethoxygrandisin B and its selectivity index (SI) against promastigote and intramacrophage amastigote forms of *Leishmania amazonensis*.

Compounds	Cytotoxicity <i>L. amazonensis</i>				
	CC <sub>50</sub> ( $\mu$ M)	Promastigote		Intracellular Amastigote	
		IC <sub>50</sub> ( $\mu$ M)	SI <sub>pro</sub>	IC <sub>50</sub> ( $\mu$ M)	SI <sub>ama</sub>
(-)-5-demethoxygrandisin B	193.37	7.0	26.6	26.04	7.4
Amphotericin B	8.82 $\mu$ M	0.02226	396.1	0.1898	46.5

Data represent mean  $\pm$  SD of at least two experiments realized in triplicate; CC<sub>50</sub>: cytotoxic concentration for 50% of peritoneal macrophages; IC<sub>50</sub>: inhibitory concentration for 50% of parasites; SI: selectivity index about cytotoxicity for the BALB/c peritoneal macrophages.


### 3.3. Nitrite Quantification in *L. amazonensis*-Infected Peritoneal Macrophages Treated with (-)-5-Demethoxygrandisin B

As shown in Figure 4, the NO levels were indirectly estimated by nitrite quantification in the supernatant of BALB/c peritoneal macrophages. An increase in the nitrite levels in the supernatant of cells treated with (-)-5-demethoxygrandisin B ( $5.75 \pm 0.24 \mu\text{M NaNO}_2$ ,  $p = 0.1587$ ) when compared to untreated cells ( $5.21 \pm 0.21 \mu\text{M NaNO}_2$ ) was observed, although this increase was not statistically significant. This effect remained even when macrophages were infected with *L. amazonensis* and treated with (-)-5-demethoxygrandisin B ( $6.67 \pm 1.53 \mu\text{M NaNO}_2$ ,  $p = 0.8286$ ) when compared to stimulated and untreated cells ( $5.69 \pm 0.20 \mu\text{M NaNO}_2$ ). Macrophages stimulated with lipopolysaccharide (LPS) showed the expected higher levels of nitrite compared to cultures not stimulated with LPS.


### 3.4. Ultrastructural Changes

A transmission electron microscopy analysis revealed untreated parasites displaying organelles with no alterations (Figure 5A), while the main alteration induced by (-)-5-demethoxygrandisin B treatment was kinetoplast swelling (Figure 5B), with alteration in a kDNA compacting pattern (yellow arrow). In addition, vacuoles (asterisks) near the flagellar pocket, vesicular electron-dense structures with an outer bilayer membrane (thin arrows), a structure that looks like an autophagosome (thick arrow), and enlargement

of the flagellar pocket with electron-dense filaments inside were also observed in the (-)-5-demethoxygrandisin B-treated parasite.



**Figure 4.** Nitrite quantification in the supernatant of BALB/c peritoneal macrophages treated with compound (-)-5-demethoxygrandisin B at 62 µM, stimulated or not with *Leishmania amazonensis*. LPS (lipopolysaccharide from *Escherichia coli*; 10 µg/mL) was used as the positive control. \*\*  $p < 0.01$  when compared with the untreated group by Mann–Whitney test.




**Figure 5.** Transmission electron microscopy analysis of *Leishmania amazonensis* promastigote forms treated with (-)-5-demethoxygrandisin B at 25 µg/mL for 24 h. (A) Untreated parasites display organelles

with no alterations. (B–D) Parasites treated with (-)-5-demethoxygrandisin B compound exhibit kinetoplast swelling (B), with altered kDNA compacting pattern (yellow arrow), vacuoles (asterisks) near flagellar pocket, vesicular electron-dense structures with outer bilayer membrane (thin arrows), a structure that looks like an autophagosome (thick arrow), and enlargement of flagellar pocket. k: kinetoplast; f: flagellum; fp: flagellar pocket; n: nucleus.

### 3.5. Mitochondrial Membrane Potential ( $\Delta\psi_m$ ) by Flow Cytometry

To investigate the influence of treatment with (-)-5-demethoxygrandisin in the mitochondrial membrane potential of *L. amazonensis* by flow cytometry,  $2 \times 10^6$  promastigotes/mL were incubated with 50 nM tetramethylrhodamine ethyl ester (TMRE), a cell-permeant fluorescent dye that is readily sequestered by active mitochondria. For this, in Figure 6, we represent the flow cytometric protocol used to assess the frequency of *Leishmania* promastigotes with mitochondrial activity (TMRE+), where a dot plot of morphological patterns of size and granularity (forward scatter (FSC) versus side scatter (SSC)) was created to define the population of *L. amazonensis* promastigotes (Region P4) (Figure 6A). From this region, we created a TMRE-PE-fluorescence histogram to quantify the TMRE+ promastigotes; Figure 5B,C represent an unstained promastigotes sample and (-)-5-demethoxygrandisin B-untreated-*L. amazonensis* promastigotes, which showed  $83.52 \pm 4.55\%$  of the TMRE+ promastigotes, respectively. The inhibition of the mitochondrial membrane potential of the heat-treated (60 °C) parasites showed a significant decrease in the  $\Delta\psi_m$  to  $49.42 \pm 1.60\%$  ( $p = 0.0286$ ) (Figure 6D). Statistically significant changes in the mitochondrial membrane potential were also observed after treatment with 7.0  $\mu\text{M}$  of (-)-5-demethoxygrandisin B ( $38.76 \pm 0.67\%$ ,  $p = 0.0286$ ) (Figure 6E,F).




**Figure 6.** Flow cytometry of mitochondrial membrane potential ( $\Delta\psi_m$ ) in promastigote forms of *Leishmania amazonensis* treated with (-)-5-demethoxygrandisin B. (A) FSC versus SSC dot plot to define *L. amazonensis*-promastigotes population. (B) TMRE-staining histogram of control samples (unstained and untreated parasites) gated on “promastigotes.” (C) TMRE-staining histogram of (-)-5-demethoxygrandisin B-untreated parasites. (D) *L. amazonensis* promastigotes treated by heat

(60 °C). (E) Representative histogram of *L. amazonensis* promastigotes treated with IC<sub>50</sub> of (-)-5-demethoxygrandisin B. (F) Statistically significant differences were observed between the percentages of cells marked with TMRE in the untreated group and the groups treated with (-)-5-demethoxygrandisin B, at the IC<sub>50</sub> concentration (7.0 μM). \*  $p < 0.05$ , when compared with the untreated group by Mann–Whitney test. Images are representative of two independent experiments carried out at least in triplicate.

### 3.6. Molecular Docking


To assess whether (-)-5-demethoxygrandisin B has potential antileishmanial activity, the enzyme trypanothione reductase (TryR) from *Leishmania infantum* was obtained from the Protein Data Bank (PDB) database under code 2JK6 [28] and selected as a molecular target for the docking simulation. The GoldScore and ChemScore scoring functions were used to predict the binding affinity of the more stable configuration of (-)-5-demethoxygrandisin B in the redox catalytic site (Cys52, Cys57, His461', and Glu466') and generated the respective scores of 52.94 and 40.76. The predicted binding modes on the docking for (-)-5-demethoxygrandisin B in the *L. infantum* TryR enzyme cavity were analyzed in the PoseView online server. As shown in Figure 7, it can be seen that the conformation of the molecule interacts with the enzyme through hydrophobic interactions with the Thr51, Cys57, and Leu334 amino acids residues and hydrogen bonds with the Lys60 and Asp327 residues.



**Figure 7.** Interactions predicted from docking simulations between the more stable configuration of (-)-5-demethoxygrandisin B and TryR enzyme. Hydrogen bond interactions are represented by dashed black lines, and hydrophobic contacts are represented by continuous green lines. The figure was generated by the PoseView online server.

### 3.7. Molecular Dynamics

From the coordinates obtained in the molecular docking procedures, the more stable configuration of (-)-5-demethoxygrandisin B was submitted to 50 ns of molecular dynamics (MD) simulations. The root mean square deviation (RMSD) values were calculated to evaluate the structural stability of the enzyme–ligand complex. The plot of the RMSD (Å) versus simulation time (ns) (Figure 8) demonstrates that the TryR–ligand complex stabilized after 20 ns, with a mean RMSD value of 2.63 Å and standard deviation  $\pm 0.41$ . Thus, it is possible to infer that the compound remained in the enzyme cavity, showing few conformational changes in the complex's structure.




**Figure 8.** Graphical representation of the root mean square deviation (RMSD) values versus simulation time for the studied complex.

To evaluate the flexibility of the protein regions concerning (-)-5-demethoxygrandisin B, the B-factor analysis was carried out. From Figure 9, we can note the complex generally presented low values of flexibility, except the region formed to the Ser76–Asn91 amino acid sequence (highlighted in red in Figure 9), which is the most flexible region of the enzyme.

### 3.8. Binding Free-Energy Calculations

The results in Table 3 show that the binding free energy by the molecular mechanics generalized Born surface area (MMGBSA) method for the TryR–(-)-5-demethoxygrandisin B complex was  $-30.41 \pm 2.79$  kcal/mol, while the  $\Delta G_{\text{bind}}$  value by the molecular mechanics Poisson–Boltzmann surface area (MMPBSA) was calculated to be  $-27.66 \pm 3.55$  kcal/mol. Furthermore, by comparing the binding free-energy values of these two methods, it is possible to observe that both are favorable and stable for the formation of the complex. Note that the van der Waals energy ( $\Delta E_{\text{vdW}}$ ) presents the greatest contribution to the total free energy, indicating that it acts as a determining factor for the affinity of (-)-5-demethoxygrandisin B for the active site of the TryR enzyme. Furthermore, electrostatic energy ( $\Delta E_{\text{ele}}$ ) and non-polar solvation energy ( $\Delta E_{\text{n-polar, GB}}/\Delta E_{\text{n-polar, PB}}$ ) also showed favorable contributions, while polar solvation energy ( $\Delta G_{\text{solv, GB}}/\Delta G_{\text{solv, PB}}$ ) and the solvation free-energy total ( $\Delta G_{\text{solv, GB}}/\Delta G_{\text{solv, PB}}$ ) showed unfavorable contributions.



**Figure 9.** Graphical representation of the structural fluctuations taking into account the enzyme's residues from the molecular dynamics simulations.

**Table 3.** Binding free energy ( $\Delta G_{\text{bind}}$ ) of the TryR(-)-5-demethoxygrandisin B more stable configuration complex and the respective energy components obtained with the MMGBSA/PBSA methods.


MMGBSA		MMPBSA	
Contribution	TryR(-)-5-Demethoxygrandisin B (kcal/mol)	Contribution	TryR(-)-5-Demethoxygrandisin B (kcal/mol)
$\Delta E_{\text{vdw}}$	-45.57 (2.33)	$\Delta E_{\text{vdw}}$	-45.57 (2.33)
$\Delta E_{\text{ele}}$	-5.10 (2.70)	$\Delta E_{\text{ele}}$	-5.10 (2.70)
$\Delta E_{\text{GB}}$	26.00 (3.17)	$\Delta E_{\text{PB}}$	29.95 (3.87)
$\Delta E_{\text{n-polar, GB}}$	-5.74 (0.25)	$\Delta E_{\text{n-polar, PB}}$	-6.94 (0.24)
$\Delta G_{\text{solv, GB}}$	20.26 (3.08)	$\Delta G_{\text{solv, PB}}$	23.01 (3.83)
$\Delta G_{\text{bind, GB}}$	-30.41 (2.79)	$\Delta G_{\text{bind, PB}}$	-27.66 (3.55)

The standard deviations are given in parentheses. MMPBSA: molecular mechanics Poisson–Boltzmann surface area; MMGBSA: molecular mechanics generalized Born surface area;  $\Delta E_{\text{vdw}}$ : van der Waals energy;  $\Delta E_{\text{ele}}$ : electrostatic energy;  $\Delta E_{\text{GB}}$ : polar solvation energy by the generalized Born method;  $\Delta E_{\text{n-polar, GB/PB}}$ : non-polar solvation energy;  $\Delta G_{\text{solv, GB/PB}}$ : total solvation free energy;  $\Delta G_{\text{bind, GB/PB}}$ : total free energy.

### 3.9. Per-Residue Energy Decomposition

Energy decomposition by residue was employed to identify the TryR enzyme residues involved in the interactions with (-)-5-demethoxygrandisin B, based on the energy contribution calculated by the MMGBSA method for the last 10 ns of the MD simulations. The binding free-energy values below -1 kcal/mol were defined as a criterion for the selection of amino acid residues that performed the most favorable interactions, that is, that contributed to the stabilization of the ligand in the complex. An analysis of the graph (Figure 10) indicates that Cys52 (-1.17 kcal/mol), Gly326 (-1.18 kcal/mol), Asp327 (-1.86 kcal/mol), Leu334 (-2.20 kcal/mol), and Thr335 (-1.59 kcal/mol) contributed most significantly to the total free energy of the complex.





**Figure 10.** Interaction plot by residues obtained by the MMBGSA method. On the right, the residues that most contributed to the binding free energy, visualized by the CHEWD plugin in the Chimera program.

#### 4. Discussion

(-)-5-demethoxygrandisin B was detected as a protonated molecule  $[M + H]^+$  of  $m/z$  403.2126 and error = 1.24 ppm. These mass spectrometry data presented high precision and accuracy in the high-resolution mass. Additionally,  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra to (-)-5-demethoxygrandisin B showed signals attributed to a tetrahydrofuran lignan. Thus, the molecular formula to (-)-5-demethoxygrandisin B was correctly attributed as  $\text{C}_{23}\text{H}_{30}\text{O}_6$ . The stereochemistry was established based on the literature data [56], i.e., the methyl groups have a *cis* relationship with the aromatic rings, because when methyl groups present a *cis* relation, the shift expected is approximately or greater than at  $\delta_{\text{H}}$  1.0, close to the signals revealed to (-)-5-demethoxygrandisin B ( $\delta_{\text{H}}$  1.06 and 1.09).

Given these considerations, it is possible to conclude that the signals in  $\delta_{\text{H}}$  4.67–4.63 are two doublets, one in  $\delta_{\text{H}}$  4.65 ( $d$ ,  $J = 4.5$  Hz,  $^1\text{H}$ ) for H-7 and the other in  $\delta_{\text{H}}$  4.63 ( $d$ ,  $J = 4.5$  Hz,  $^1\text{H}$ ) for H-7'. The coupling constant ( $J = 4.5$  Hz) is by the Karplus vicinal correlation [58], where these hydrogens are expected to have a smaller dihedral angle with their respective vicinal hydrogens H-8 and H-8', in the *gauche* position. Lopes et. al. [12], when isolating 3,4,5,3',4'-pentamethoxy-5-demethoxygrandisin, assigned to carbons C-7 and C-7' the signals at  $\delta_{\text{C}}$  88.36 and 88.49, respectively. Therefore, the carbon signals at  $\delta_{\text{C}}$  88.35 and 88.47 of the  $^{13}\text{C}$  NMR spectrum of (-)-5-demethoxygrandisin B were attributed to carbons C-7 and C-7', respectively. To determine the conformation of the tetrahydrofuran ring of (-)-5-demethoxygrandisin B, the four chiral centers of the substance (C-7, C-7', C-8, C-8') were considered, so there are several possible isomers; however, when performing projections and taking into account the coupling constant of H-7 and H-7' ( $J = 4.5$  Hz), where vicinal hydrogens are expected to be in the *cis* position, only two possible pairs of enantiomers remain.

$^{13}\text{C}$  NMR studies carried out by Fonseca [57] concluded that tetrahydrofuran lignans with the ferryl group in the equatorial position present a C-1 or C-1' carbon signal shift at  $\delta_{\text{C}}$  134.6, while for (-)-5-demethoxygrandisin B it is observed that the C-1' car-

bon showed a signal at  $\delta_C$  134.86, suggesting that the aryl group attached to C-1' is in the pseudoequatorial position. Fonseca [57] also carried out  $^{13}\text{C}$  NMR studies for the methyl groups of the aforementioned lignans, where the methyl groups presented the following displacements for carbon: in structure I at  $\delta_C$  13.7; in structure II at  $\delta_C$  12.9; and in structure III at  $\delta_C$  11.6. Therefore, it is observed that when the methyl groups are in the *trans* position there is a greater chemical shift for the respective carbon signals. For (-)-5-demethoxygrandisin B, it was observed in the  $^{13}\text{C}$  NMR spectrum that the methyl groups presented signals at  $\delta_C$  13.83 and 14.07, thus concluding that they are in the *trans* position. Thus, there are the following possibilities for determining the absolute configuration of (-)-5-demethoxygrandisin B: 7S,8R,7'S,8'R or 7R,8S,7'R,8'S. As the substance presented an optical rotation  $[\alpha]_D = -11.15^\circ$  (MeOH) and according to the studies by Kubanek et al. [59], Kubanek et al. [60], Hwang et al. [61], and Biftu et al. [62], tetrahydrofuran lignans with absolute configuration 7S,8R,7'S,8'R present optical rotation (+), while with absolute configuration 7R,8S,7'R,8'S present optical rotation (-); therefore, for (-)-5-demethoxygrandisin B which showed optical rotation (-), the absolute configuration of said substance is 7R,8S,7'R,8'S. This is where the meeting of the cited analyses allowed us to conclude that (-)-5-demethoxygrandisin B is the lignan (7R,8S,7'R,8'S)-3,4,5,3',4'-pentamethoxy-7,7'-epoxylignan (Figure 2).

Excitedly, the tetrahydrofuran lignan (-)-5-demethoxygrandisin B isolated in *V. surinamensis* leaves demonstrated leishmanicidal activity. Grandisin, another tetrahydrofuran neolignan found in *V. surinamensis* and *Piper solmsianum*, exhibits potent trypanocidal activity against trypomastigote forms of *Trypanosoma cruzi* and shows promising potential for applications in medicine as an antileishmanial agent [63]. The literature data report that lignans have excellent potential as growth inhibitors for the promastigote and intracellular amastigote stage of *Leishmania* [64,65]. The present data showed that the selectivity index for (-)-5-demethoxygrandisin B was more prominent for *Leishmania* than for macrophages. Ten lignans isolated from the hexane-ethyl acetate extract of *Phyllanthus amarus* leaves showed that the  $\text{CC}_{50}$  for all the samples was  $>100 \mu\text{g}/\text{mL}$ , thus revealing low cytotoxicity against macrophages and selectivity against the parasite [66].

(-)-5-demethoxygrandisin B showed greater selectivity against the promastigote stage of *L. amazonensis* compared to the intracellular amastigote, demonstrating the direct action of this compound on this parasite. This can also be attributed to the lower compound bioavailability within the macrophage, which may have resulted in reduced activity against the intracellular amastigote. An indirect mechanism involved with the inhibition of intracellular amastigotes is related to macrophage activation, especially the induction of nitric oxide (NO) [22]. However, there were no significant changes in this assessment parameter when we analyzed the nitrite quantification of *L. amazonensis*-stimulated peritoneal macrophages treated with (-)-5-demethoxygrandisin B.

Therefore, to understand the leishmanicidal activity of the (-)-5-demethoxygrandisin B against promastigote forms, observations of ultrastructural and morphological alterations were performed as a direct way to determine parasite inhibition. Our observations revealed the presence of numerous large vacuoles, vesicular structures with electron-dense content and outer bilayer membranes, autophagosome-like structures, and an enlargement of the flagellar pocket with electron-dense filaments inside it. However, the most significant alteration was observed in the mitochondrion/kinetoplast, which displayed swelling and an altered kDNA compacting pattern. *Leishmania* parasites, like other species of trypanosomatids, have a single mitochondrion with specific energetic and antioxidant enzymes that regulate oxidative stress and bioenergetics and a unique arrangement of mitochondrial DNA (kinetoplast DNA). The kDNA is visible as a prominent disk-shaped spot located in the paraflagellar region of the single elongated mitochondrion, and its gene encoding information is far from that set needed for mitochondrial processes, revealing its importance in the regulation of pro- and antioxidant processes not only in the mitochondria [67,68]. The mitochondrial differences between mammals and trypanosomatids make this organelle

a natural drug target, and the observed ultrastructural alteration led us to evaluate the mitochondrial membrane potential of parasites treated with (-)-5-demethoxygrandisin B.

Our results show that (-)-5-demethoxygrandisin B induced the depolarization of the mitochondrial membrane of the promastigote parasite, suggesting inhibition of the metabolic activity of parasites. *L. amazonensis* promastigotes treated with compounds like lignans change the mitochondrial membrane potential and lower ATP production [66]. Impairment of the membrane potential allows compounds to cross the mitochondrial membrane which may lead to a loss of the impermeability to intracellular electrolytes and consequently leads to inhibition of ATP production, resulting in parasite death [69–71]. This decrease in mitochondrial membrane potential can occur due to the oxidative imbalance caused by competitively inhibiting TryR activity, a pathway responsible for the leishmanicidal effect [72].

The TryR enzyme plays a crucial role in the antioxidant defense of trypanosomatids and has been widely used in molecular modeling studies in the literature [73,74]. Tetrahydrofuran lignans isolated from *V. surinamensis* showed potent trypanocidal activity against the trypomastigote form of *T. cruzi* [11]. A study by Oliveira et al. [75] suggests that the inhibition of *T. cruzi* TryR is related to the trypanocidal action of these lignans. Thus, to try to understand the inhibition mechanism of the compound against *Leishmania*, the enzyme TryR from *L. infantum* (PDB ID 2JK6) was selected as a molecular target for the docking simulation.

In this sense, the links with the residues Thr51, Lys60, Asp327, and Leu334 observed in the docking are considered important for biological activity against the TryR enzyme, as they participate in the binding of the FAD cofactor at its respective site. It is worth noting that the catalytic mechanism of the TryR occurs due to the transfer of electrons from NADPH via FAD to the two catalytic cysteines (Cys52 and Cys57), and the possible interference in this process prevents the reduction in the disulfide bridge [34]. Furthermore, the interaction with Cys57 is crucial for the potential inhibition of the enzyme as it makes the inactivation of the catalytic cysteine possible and thus stops the nucleophilic attack on Cys52 necessary for the release of the reduced substrate (T[SH]2) [17]. Therefore, it is observed that the more stable configuration obtained by the molecular docking of (-)-5-demethoxygrandisin B has an affinity for the amino acid residues of the active site and performs interactions with a catalytic cysteine considered important for the enzymatic activity.

In evaluating the MD simulations, it was found that the complex exhibited a high B-factor value due to its location in the N-terminal portion of an  $\alpha$ -helix loop [76]. The studies carried out by Kuldeep et al. [74] report that the structure of the TryR enzyme of *L. infantum* shows characteristic fluctuations in the N- and C-terminal regions, mainly caused by the presence of unstable loops in these positions.

The binding affinity between the studied compound and the macromolecule was determined by calculating the binding free energy, which is an important tool for designing potent enzymatic inhibitors [77]. The amino acids Cys52, Gly326, Asp327, Leu334, and Thr335 contributed to the stabilization of the (-)-5-demethoxygrandisin B ligand in the complex. These key residues played an important role in stabilizing the ligand in the active site of the TryR enzyme, where they are located. Furthermore, the MD results corroborate those obtained in the molecular docking, which also identified interactions with Gly326, Asp327, and Leu334. Residues Gly326, Asp327, and Leu334 are part of the FAD cofactor binding site, whose interactions are also considered relevant for molecular recognition and the binding affinity of inhibitors [78]. The contribution of Cys52 suggests potential bioactivity of the more stable configuration of (-)-5-demethoxygrandisin B against the TryR enzyme, as this binding prevents the reaction of cysteine with the T[S]2 substrates for the production of mixed disulfide and, consequently, inhibits enzymatic activity [79]. A potent inhibitor studied by Baiocco et al. [28] presents a tetrahedral geometry at the redox site, whose active conformation is oriented by binding to catalytic residues and Thr335, demonstrating the significant role of this amino acid for the antileishmanial activity of drug candidates. A study carried out by Feitosa et al. [80] showed from the interaction

energy analysis per residue that the contributions of Gly326 and Thr335 are responsible for the permanence of the ligand in the TryR site. Therefore, the results corroborate previous studies investigating the trypanothione catalytic mechanism and provide a theoretical basis for the design of lignan (-)-5-demethoxygrandisin B as a potential inhibitor of the TryR enzyme of *L. infantum*.

## 5. Conclusions

The (7R,8S,7'R,8'S)-3,4,5,3',4'-pentamethoxy-7,7'-epoxylignan, namely (-)-5-demethoxygrandisin B, isolated from the leaves of *V. surinamensis* showed to be selective for the parasites, inhibiting the promastigote and intracellular amastigote forms of *L. amazonensis*. The antiparasitic effect of this compound was confirmed by the ultrastructural changes with decreased mitochondrial membrane potential in *L. amazonensis* promastigotes. The docking analyses and molecular dynamics simulation showed a possible mechanism of inhibition promoted by a more thermodynamically stable conformation of (-)-5-demethoxygrandisin B to the TryR enzyme.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/pharmaceutics15092292/s1>, Figure S1: Mass spectrum of the precursor ion (-)-5-demethoxygrandisin B and its isotopes; Figure S2: <sup>1</sup>H NMR for the (-)-5-demethoxygrandisin B in CDCl<sub>3</sub> (400 MHz); Figure S3: <sup>13</sup>C NMR for the (-)-5-demethoxygrandisin B in CDCl<sub>3</sub> (100 MHz); Figure S4: COSY for the (-)-5-demethoxygrandisin B in CDCl<sub>3</sub>; Figure S5: HSQC for the (-)-5-demethoxygrandisin B in CDCl<sub>3</sub>; Figure S6: HMBC for the (-)-5-demethoxygrandisin B in CDCl<sub>3</sub>.

**Author Contributions:** Conceptualization, S.S.P. and J.V.S.-S.; data curation, L.S.S., F.A.d.M., A.L.B., and F.A.-S.; formal analysis, L.S.S., F.A.d.M., A.L.B., K.d.S.C. and F.A.-S.; funding acquisition, L.S.S., K.d.S.C. and F.A.-S.; investigation, S.S.P., J.V.S.-S., L.O.d.S., A.P.L.d.C., M.L.L.J., P.W.P.G., D.d.J.H., C.J.M.-T. and N.N.T.; methodology, S.S.P., J.V.S.-S., L.O.d.S. and F.A.d.M.; project administration, L.S.S., F.A.d.M., K.d.S.C. and F.A.-S.; resources, N.N.T., A.L.B., L.S.S., F.A.d.M., K.d.S.C. and F.A.-S.; software, S.S.P., A.P.L.d.C. and F.A.d.M.; supervision, L.S.S., F.A.d.M., K.d.S.C. and F.A.-S.; validation, L.S.S., F.A.d.M., A.L.B., N.N.T., K.d.S.C. and F.A.-S.; visualization, S.S.P., P.W.P.G. and J.V.S.-S.; writing—original draft preparation, S.S.P., P.W.P.G. and J.V.S.-S.; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.

**Funding:** Pró-reitoria de Pesquisa—Universidade Federal do Pará (UFPA), Oswaldo Cruz Institute, Coordination for the Improvement of Higher Education Personnel (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior do Brazil; CAPES), grant number 8887.200524/2018-00, 88887.368507/2019-00, Finance Code 001, and Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; FAPERJ), grant numbers E-26/210.344/2019, E-26/201.765/2019, and E-26/211.680/2021 (269680). The CytoFlex flow cytometer used at the Flow Cytometry Core Facility was acquired by FAPERJ, grant number E-26/110332/2014. The APC (Fund for Conjoint Research Project) was funded by the Oswaldo Cruz Institute/FIOCRUZ. F.A.-S. is a postdoctoral research fellow and scholarship holder of CAPES, grant number 88887.363006/2019-00. K.S.C. (CNPq 315225/2021-1) is a senior researcher.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All supporting data used in this study are available from the authors.

**Acknowledgments:** The authors would like to express their deepest gratitude to Pró-Reitoria de Pesquisa (Propesp) of the Federal University of Para (UFPA) and Instituto Oswaldo Cruz of the Oswaldo Cruz Foundation (IOC/FICORUZ) and Vanessa Costa and Raquel Paredes of the Flow Cytometry Core Facility for acquisition of the CytoFlex flow cytometer.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Schultes, R.E. A New Narcotic Snuff from the Northwest Amazon. *Bot. Mus. Lealf. Harv. Univ.* **1954**, *16*, 241–260. [[CrossRef](#)]
2. Rodrigues, W.A. Revisão Taxonômica Das Espécies de *Virola aublet* (Myristicaceae) Do Brasil. *Acta. Amaz.* **1980**, *10*, 3–127. [[CrossRef](#)]
3. Ferri, P.H.; Barata, L.E.S. Neolignans and a Phenylpropanoid from *Virola Pavonis* Leaves. *Phytochemistry* **1992**, *31*, 1375–1377. [[CrossRef](#)]
4. Lopes, L.M.X.; Yoshida, M.; Gottlieb, O.R. 1,11-Diarylundecan-1-One and 4-Aryltetralone Neolignans from *Virola Sebifera*. *Phytochemistry* **1982**, *21*, 751–755. [[CrossRef](#)]
5. Lopes, N.P.; dos Santos, P.A.; Kato, M.J.; Yoshida, M. New Butenolides in Plantlets of *Virola Surinamensis* (Myristicaceae). *Chem. Pharm. Bull.* **2004**, *52*, 1255–1257. [[CrossRef](#)]
6. Rye, C.E.; Barker, D. Asymmetric Synthesis and Anti-Protozoal Activity of the 8,4'-Oxyneolignans Virolin, Surinamensin and Analogues. *Eur. J. Med. Chem.* **2013**, *60*, 240–248. [[CrossRef](#)] [[PubMed](#)]
7. Messiano, G.B.; Santos, R.A.d.S.; Ferreira, L.D.S.; Simões, R.A.; Jabor, V.A.P.; Kato, M.J.; Lopes, N.P.; Pupo, M.T.; de Oliveira, A.R.M. In Vitro Metabolism Study of the Promising Anticancer Agent the Lignan (–)-Grandisin. *J. Pharm. Biomed. Anal.* **2013**, *72*, 240–244. [[CrossRef](#)] [[PubMed](#)]
8. Carvalho, A.A.V.; Galdino, P.M.; Nascimento, M.V.M.; Kato, M.J.; Valadares, M.C.; Cunha, L.C.; Costa, E.A. Antinociceptive and Antiinflammatory Activities of Grandisin Extracted from *Virola surinamensis*. *Phytother. Res.* **2010**, *24*, 113–118. [[CrossRef](#)] [[PubMed](#)]
9. Lopes, N.P.; Kato, M.J.; de Andrade, E.H.A.; Maia, J.G.S.; Yoshida, M.; Planchart, A.R.; Katzin, A.M. Antimalarial Use of Volatile Oil from Leaves of *Virola Surinamensis* (Rol.) Warb. by Waiãpi Amazon Indians. *J. Ethnopharmacol.* **1999**, *67*, 313–319. [[CrossRef](#)] [[PubMed](#)]
10. Cabral, M.M.O.; Barbosa-Filho, J.M.; Maia, G.L.A.; Chaves, M.C.O.; Braga, M.V.; De Souza, W.; Soares, R.O.A. Neolignans from Plants in Northeastern Brazil (Lauraceae) with Activity against *Trypanosoma Cruzi*. *Exp. Parasitol.* **2010**, *124*, 319–324. [[CrossRef](#)]
11. Lopes, N.; Chicaro, P.; Kato, M.; Albuquerque, S.; Yoshida, M. Flavonoids and Lignans from *Virola surinamensis* Twigs and Their In Vitro Activity against *Trypanosoma cruzi*. *Planta Med.* **1998**, *64*, 667–669. [[CrossRef](#)]
12. Lopes, N.P.; de Almeida Blumenthal, E.E.; Cavalheiro, A.J.; Kato, M.J.; Yoshida, M. Lignans,  $\gamma$ -Lactones and Propiophenones of *Virola Surinamensis*. *Phytochemistry* **1996**, *43*, 1089–1092. [[CrossRef](#)]
13. dos Santos Maia, M.; Raimundo e Silva, J.P.; de Lima Nunes, T.A.; Saraiva de Sousa, J.M.; Soares Rodrigues, G.C.; Messias Monteiro, A.F.; Fachine Tavares, J.; da Franca Rodrigues, K.A.B.; Mendonça-Junior, F.J.; Scotti, L.; et al. Virtual Screening and the In Vitro Assessment of the Antileishmanial Activity of Lignans. *Molecules* **2020**, *25*, 2281. [[CrossRef](#)] [[PubMed](#)]
14. Mann, S.; Frasca, K.; Scherrer, S.; Henao-Martínez, A.F.; Newman, S.; Ramanan, P.; Suarez, J.A. A Review of Leishmaniasis: Current Knowledge and Future Directions. *Curr. Trop. Med. Rep.* **2021**, *8*, 121–132. [[CrossRef](#)] [[PubMed](#)]
15. WHO. Leishmaniasis. Available online: <https://www.who.int/news-room/fact-sheets/detail/leishmaniasis> (accessed on 15 March 2023).
16. Imran, M.; Khan, S.A.; Abida; Alshrari, A.S.; Eltahir Mudawi, M.M.; Alshammari, M.K.; Harshan, A.A.; Alshammari, N.A. Small Molecules as Kinetoplastid Specific Proteasome Inhibitors for Leishmaniasis: A Patent Review from 1998 to 2021. *Expert. Opin. Ther. Pat.* **2022**, *32*, 591–604. [[CrossRef](#)] [[PubMed](#)]
17. Battista, T.; Colotti, G.; Ilari, A.; Fiorillo, A. Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiasis. *Molecules* **2020**, *25*, 1924. [[CrossRef](#)] [[PubMed](#)]
18. Fiorillo, A.; Colotti, G.; Exertier, C.; Liuzzi, A.; Seghetti, F.; Salerno, A.; Caciolla, J.; Ilari, A. Innovative Approach for a Classic Target: Fragment Screening on Trypanothione Reductase Reveals New Opportunities for Drug Design. *Front. Mol. Biosci.* **2022**, *9*, 900882. [[CrossRef](#)]
19. Gomes, P.; Quirós-Guerrero, L.; Muribeca, A.; Reis, J.; Pamplona, S.; Lima, A.; Trindade, M.; Silva, C.; Souza, J.; Boutin, J.; et al. Constituents of *Chamaecrista diphylla* (L.) Greene Leaves with Potent Antioxidant Capacity: A Feature-Based Molecular Network Dereplication Approach. *Pharmaceutics* **2021**, *13*, 681. [[CrossRef](#)]
20. Gomes, P.; Quirós-Guerrero, L.; Silva, C.; Pamplona, S.; Boutin, J.A.; Eberlin, M.; Wolfender, J.-L.; Silva, M. Feature-Based Molecular Network-Guided Dereplication of Natural Bioactive Products from Leaves of *Stryphnodendron pulcherrimum* (Willd.) Hochr. *Metabolites* **2021**, *11*, 281. [[CrossRef](#)] [[PubMed](#)]
21. Silva-Silva, J.V.; Moragas-Tellis, C.J.; Chagas, M.D.S.d.S.; de Souza, P.V.R.; Souza, C.d.S.F.d.; Haridoim, D.d.J.; Taniwaki, N.N.; Moreira, D.d.L.; Behrens, M.D.; Calabrese, K.d.S.; et al. Antileishmanial Activity of Flavones-Rich Fraction From *Arrabidaea chica* Verlot (Bignoniaceae). *Front. Pharmacol.* **2021**, *12*, 703985. [[CrossRef](#)] [[PubMed](#)]
22. Silva-Silva, J.V.; Moragas-Tellis, C.J.; Chagas, M.S.S.; Souza, P.V.R.; Moreira, D.L.; de Souza, C.S.F.; Teixeira, K.F.; Cenci, A.R.; de Oliveira, A.S.; Almeida-Souza, F.; et al. Carajurin: A Anthocyanidin from *Arrabidaea chica* as a Potential Biological Marker of Antileishmanial Activity. *Biomed. Pharmacother.* **2021**, *141*, 111910. [[CrossRef](#)] [[PubMed](#)]
23. Ramos, G.d.C.; Silva-Silva, J.V.; Watanabe, L.A.; de Sousa Siqueira, J.E.; Almeida-Souza, F.; Calabrese, K.S.; do Rosario Marinho, A.M.; Marinho, P.S.B.; de Oliveira, A.S. Phomoxanthone A, Compound of Endophytic Fungi *Paecilomyces* Sp. and Its Potential Antimicrobial and Antiparasitic. *Antibiotics* **2022**, *11*, 1332. [[CrossRef](#)]

24. Pina, J.R.S.; Silva-Silva, J.V.; Carvalho, J.M.; Bitencourt, H.R.; Watanabe, L.A.; Fernandes, J.M.P.; Souza, G.E.d.; Aguiar, A.C.C.; Guido, R.V.C.; Almeida-Souza, F.; et al. Antiprotozoal and Antibacterial Activity of Ravenelin, a Xanthone Isolated from the Endophytic Fungus *Exserohilum Rostratum*. *Molecules* **2021**, *26*, 3339. [[CrossRef](#)] [[PubMed](#)]
25. Silva-Silva, J.V.; Moreira, R.F.; Watanabe, L.A.; de Souza, C.D.S.F.; Hardoim, D.J.; Taniwaki, N.N.; Bertho, A.L.; Teixeira, K.F.; Cenci, A.R.; Doring, T.H.; et al. Monomethylsulochrin Isolated from Biomass Extract of *Aspergillus* Sp. against *Leishmania Amazonensis*: In Vitro Biological Evaluation and Molecular Docking. *Front. Cell. Infect. Microbiol.* **2022**, *12*, 974910. [[CrossRef](#)]
26. Silva-Silva, J.V.; Moragas-Tellis, C.J.; Chagas, M.S.S.; Souza, P.V.R.; Moreira, D.L.; Hardoim, D.J.; Taniwaki, N.N.; Costa, V.F.A.; Bertho, A.L.; Brondani, D.; et al. Carajurin Induces Apoptosis in *Leishmania amazonensis* Promastigotes through Reactive Oxygen Species Production and Mitochondrial Dysfunction. *Pharmaceutics* **2022**, *15*, 331. [[CrossRef](#)] [[PubMed](#)]
27. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking 1 Edited by F. E. Cohen. *J. Mol. Biol.* **1997**, *267*, 727–748. [[CrossRef](#)]
28. Baiocco, P.; Colotti, G.; Franceschini, S.; Ilari, A. Molecular Basis of Antimony Treatment in Leishmaniasis. *J. Med. Chem.* **2009**, *52*, 2603–2612. [[CrossRef](#)]
29. Lodhi, S.S.; Farmer, R.; Singh, A.K.; Jaiswal, Y.K.; Wadhwa, G. 3D Structure Generation, Virtual Screening and Docking of Human Ras-Associated Binding (Rab3A) Protein Involved in Tumourigenesis. *Mol. Biol. Rep.* **2014**, *41*, 3951–3959. [[CrossRef](#)]
30. Ruiz-Santaquiteria, M.; de Castro, S.; Toro, M.A.; de Lucio, H.; Gutiérrez, K.J.; Sánchez-Murcia, P.A.; Jiménez, M.Á.; Gago, F.; Jiménez-Ruiz, A.; Camarasa, M.-J.; et al. Trypanothione Reductase Inhibition and Anti-Leishmanial Activity of All-Hydrocarbon Stapled  $\alpha$ -Helical Peptides with Improved Proteolytic Stability. *Eur. J. Med. Chem.* **2018**, *149*, 238–247. [[CrossRef](#)]
31. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A Visualization System for Exploratory Research and Analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612. [[CrossRef](#)]
32. Halgren, T.A. Merck Molecular Force Field. I. Basis, Form, Scope, Parameterization, and Performance of MMFF94. *J. Comput. Chem.* **1996**, *17*, 490–519. [[CrossRef](#)]
33. Hanwell, M.D.; Curtis, D.E.; Lonie, D.C.; Vandermeersch, T.; Zurek, E.; Hutchison, G.R. Avogadro: An Advanced Semantic Chemical Editor, Visualization, and Analysis Platform. *J. Cheminform.* **2012**, *4*, 17. [[CrossRef](#)]
34. Ilari, A.; Fiorillo, A.; Genovese, I.; Colotti, G. Polyamine-Trypanothione Pathway: An Update. *Future Med. Chem.* **2017**, *9*, 61–77. [[CrossRef](#)]
35. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved Protein-Ligand Docking Using GOLD. *Proteins* **2003**, *52*, 609–623. [[CrossRef](#)]
36. Stierand, K.; Maaß, P.C.; Rarey, M. Molecular Complexes at a Glance: Automated Generation of Two-Dimensional Complex Diagrams. *Bioinformatics* **2006**, *22*, 1710–1716. [[CrossRef](#)] [[PubMed](#)]
37. Stierand, K.; Rarey, M. From Modeling to Medicinal Chemistry: Automatic Generation of Two-Dimensional Complex Diagrams. *ChemMedChem* **2007**, *2*, 853–860. [[CrossRef](#)] [[PubMed](#)]
38. Frisch, M.J.; Frisch, M.; Trucks, G.; Schlegel, K.; Scuseria, G.; Robb, M.; Cheeseman, J.; Montgomery, J.; Vreven, T.; Kudin, K.-N.; et al. *Gaussian 03: Revision C.02*; Gaussian Inc.: Pittsburgh, PA, USA, 2003.
39. Bayly, C.I.; Cieplak, P.; Cornell, W.; Kollman, P.A. A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges: The RESP Model. *J. Phys. Chem.* **1993**, *97*, 10269–10280. [[CrossRef](#)]
40. Hariharan, P.C.; Pople, J.A. The Influence of Polarization Functions on Molecular Orbital Hydrogenation Energies. *Theor. Chim. Acta* **1973**, *28*, 213–222. [[CrossRef](#)]
41. Li, H.; Robertson, A.D.; Jensen, J.H. Very Fast Empirical Prediction and Rationalization of Protein PKa Values. *Proteins* **2005**, *61*, 704–721. [[CrossRef](#)] [[PubMed](#)]
42. Salomon-Ferrer, R.; Götz, A.W.; Poole, D.; Le Grand, S.; Walker, R.C. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. *J. Chem. Theory Comput.* **2013**, *9*, 3878–3888. [[CrossRef](#)]
43. Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and Testing of a General Amber Force Field. *J. Comput. Chem.* **2004**, *25*, 1157–1174. [[CrossRef](#)] [[PubMed](#)]
44. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of Multiple Amber Force Fields and Development of Improved Protein Backbone Parameters. *Proteins* **2006**, *65*, 712–725. [[CrossRef](#)]
45. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of Simple Potential Functions for Simulating Liquid Water. *J. Chem. Phys.* **1983**, *79*, 926–935. [[CrossRef](#)]
46. Case, D.A.; Cheatham, T.E.; Darden, T.; Gohlke, H.; Luo, R.; Merz, K.M.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R.J. The Amber Biomolecular Simulation Programs. *J. Comput. Chem.* **2005**, *26*, 1668–1688. [[CrossRef](#)] [[PubMed](#)]
47. Loncharich, R.J.; Brooks, B.R.; Pastor, R.W. Langevin Dynamics of Peptides: The Frictional Dependence of Isomerization Rates Of N-Acetylalanine-N-Methylamide. *Biopolymers* **1992**, *32*, 523–535. [[CrossRef](#)] [[PubMed](#)]
48. Darden, T.; York, D.; Pedersen, L. Particle Mesh Ewald: An  $N \cdot \log(N)$  Method for Ewald Sums in Large Systems. *J. Chem. Phys.* **1993**, *98*, 10089–10092. [[CrossRef](#)]
49. Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H.J.C. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes. *J. Comput. Phys.* **1977**, *23*, 327–341. [[CrossRef](#)]
50. Verlet, L. Computer “Experiments” on Classical Fluids. II. Equilibrium Correlation Functions. *Phys. Rev.* **1968**, *165*, 201–214. [[CrossRef](#)]

51. Roe, D.R.; Cheatham, T.E. PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. *J. Chem. Theory Comput.* **2013**, *9*, 3084–3095. [[CrossRef](#)]
52. Kollman, P.A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; et al. Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models. *ACC Chem. Res.* **2000**, *33*, 889–897. [[CrossRef](#)]
53. Massova, I.; Kollman, P.A. Combined Molecular Mechanical and Continuum Solvent Approach (MM-PBSA/GBSA) to Predict Ligand Binding. *Perspect. Drug Discov. Des.* **2000**, *18*, 113–135. [[CrossRef](#)]
54. Miller, B.R.; McGee, T.D.; Swails, J.M.; Homeyer, N.; Gohlke, H.; Roitberg, A.E. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. *J. Chem. Theory Comput.* **2012**, *8*, 3314–3321. [[CrossRef](#)]
55. Raza, S.; Ranaghan, K.E.; van der Kamp, M.W.; Woods, C.J.; Mulholland, A.J.; Azam, S.S. Visualizing Protein–Ligand Binding with Chemical Energy-Wise Decomposition (CHEWD): Application to Ligand Binding in the Kallikrein-8 S1 Site. *J. Comput. Aided Mol. Des.* **2019**, *33*, 461–475. [[CrossRef](#)]
56. Barata, L.E.S.; Baker, P.M.; Gottlieb, O.R.; Rùveda, E.A. Neolignans of *Virola Surinamensis*. *Phytochemistry* **1978**, *17*, 783–786. [[CrossRef](#)]
57. Fonseca, S.F. 1945-RMN-13c de Lignanas Da Araucaria Angustifolia, de Neolignanas Ariltetralinicas e Tetraidrofuránicas e de Derivados Da Podofilotoxina. Tese (Doutorado), Universidade Estadual de Campinas, Campinas, Brazil, 1980. [[CrossRef](#)]
58. Karplus, M. Contact Electron-Spin Coupling of Nuclear Magnetic Moments. *J. Chem. Phys.* **1959**, *30*, 11–15. [[CrossRef](#)]
59. Kubanek, J.; Hay, M.E.; Brown, P.J.; Lindquist, N.; Fenical, W. Lignoid Chemical Defenses in the Freshwater Macrophyte *Saururus Cernuus*. *Chemoecology* **2001**, *11*, 1–8. [[CrossRef](#)]
60. Kubanek, J.; Fenical, W.; Hay, M.E.; Brown, P.J.; Lindquist, N. Two Antifeedant Lignans from the Freshwater Macrophyte *Saururus Cernuus*. *Phytochemistry* **2000**, *54*, 281–287. [[CrossRef](#)]
61. Hwang, B.Y.; Lee, J.-H.; Nam, J.B.; Hong, Y.-S.; Lee, J.J. Lignans from *Saururus Chinensis* Inhibiting the Transcription Factor NF- $\kappa$ B. *Phytochemistry* **2003**, *64*, 765–771. [[CrossRef](#)] [[PubMed](#)]
62. Biftu, T.; Hazra, B.G.; Stevenson, R.; Williams, J.R. Syntheses of Lignans from 2,3-Diarolybutanes. *J. Chem. Soc. Perkin. Trans. 1* **1978**, 1147–1150. [[CrossRef](#)]
63. Patel, D.K. Grandisin and Its Therapeutic Potential and Pharmacological Activities: A Review. *Pharmacol. Res. Mod. Chin. Med.* **2022**, *5*, 100176. [[CrossRef](#)]
64. Veiga, A.; Albuquerque, K.; Corrêa, M.E.; Brigido, H.; Silva e Silva, J.; Campos, M.; Silveira, F.; Santos, L.; Dolabela, M. Leishmania Amazonensis and Leishmania Chagasi: In Vitro Leishmanicide Activity of *Virola Surinamensis* (Rol.) Warb. *Exp. Parasitol.* **2017**, *175*, 68–73. [[CrossRef](#)] [[PubMed](#)]
65. Gervazoni, L.F.O.; Barcellos, G.B.; Ferreira-Paes, T.; Almeida-Amaral, E.E. Use of Natural Products in Leishmaniasis Chemotherapy: An Overview. *Front. Chem.* **2020**, *8*, 579891. [[CrossRef](#)]
66. Conrado, G.G.; Grazzia, N.; de Oliveira, A.d.S.S.; Franco, C.H.; Moraes, C.B.; Gadelha, F.R.; Miguel, D.C.; Garcia, V.L. Prospecting and Identifying *Phyllanthus Amarus* Lignans with Antileishmanial and Antitrypanosomal Activity. *Planta Med.* **2020**, *86*, 782–789. [[CrossRef](#)]
67. Lukeš, J.; Hashimi, H.; Zíková, A. Unexplained Complexity of the Mitochondrial Genome and Transcriptome in Kinetoplastid Flagellates. *Curr. Genet.* **2005**, *48*, 277–299. [[CrossRef](#)] [[PubMed](#)]
68. Menna-Barreto, R.F.S.; de Castro, S.L. The Double-Edged Sword in Pathogenic Trypanosomatids: The Pivotal Role of Mitochondria in Oxidative Stress and Bioenergetics. *Biomed. Res. Int.* **2014**, *2014*, 614014. [[CrossRef](#)] [[PubMed](#)]
69. Rottini, M.M.; Amaral, A.C.F.; Ferreira, J.L.P.; de Andrade Silva, J.R.; Taniwaki, N.N.; da Silva Freitas de Souza, C.; d’Ecoffier, L.N.; Almeida-Souza, F.; de Jesus Haridoim, D.; da Costa, S.C.G.; et al. In Vitro Evaluation of (-)- $\alpha$ -Bisabolol as a Promising Agent against *Leishmania Amazonensis*. *Exp. Parasitol.* **2015**, *148*, 66–72. [[CrossRef](#)] [[PubMed](#)]
70. de Medeiros, M.d.G.F.; da Silva, A.C.; Citó, A.M. das G.L.; Borges, A.R.; de Lima, S.G.; Lopes, J.A.D.; Figueiredo, R.C.B.Q. In Vitro Antileishmanial Activity and Cytotoxicity of Essential Oil from *Lippia sidoides* Cham. *Parasitol. Int.* **2011**, *60*, 237–241. [[CrossRef](#)]
71. Teixeira de Macedo Silva, S.; Visbal, G.; Lima Prado Godinho, J.; Urbina, J.A.; de Souza, W.; Cola Fernandes Rodrigues, J. In Vitro Antileishmanial Activity of Ravuconazole, a Triazole Antifungal Drug, as a Potential Treatment for Leishmaniasis. *J. Antimicrob. Chemother.* **2018**, *73*, 2360–2373. [[CrossRef](#)]
72. Inacio, J.D.F.; Fonseca, M.S.; Limaverde-Sousa, G.; Tomas, A.M.; Castro, H.; Almeida-Amaral, E.E. Epigallocatechin-O-3-Gallate Inhibits *Trypanothione reductase* of *Leishmania infantum*, Causing Alterations in Redox Balance and Leading to Parasite Death. *Front. Cell. Infect. Microbiol.* **2021**, *11*, 640561. [[CrossRef](#)] [[PubMed](#)]
73. Tonelli, M.; Sparatore, A.; Basilico, N.; Cavicchini, L.; Parapini, S.; Tasso, B.; Laurini, E.; Pricl, S.; Boido, V.; Sparatore, F. Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity. *Pharmaceutics* **2020**, *13*, 339. [[CrossRef](#)]
74. Kuldeep, J.R.; Karthik, R.; Kaur, P.; Goyal, N.; Siddiqi, M.I. Identification of Potential Anti-Leishmanial Agents Using Computational Investigation and Biological Evaluation against *Trypanothione reductase*. *J. Biomol. Struct. Dyn.* **2021**, *39*, 960–969. [[CrossRef](#)]
75. De Oliveira, R.B.; Vaz, A.B.; Alves, R.O.; Liarte, D.B.; Donnici, C.L.; Romanha, A.J.; Zani, C.L. Arylfurans as Potential Trypanosoma Cruzi Trypanothione Reductase Inhibitors. *Mem. Inst. Oswaldo Cruz.* **2006**, *101*, 169–173. [[CrossRef](#)] [[PubMed](#)]

76. Colotti, G.; Baiocco, P.; Fiorillo, A.; Boffi, A.; Poser, E.; Di Chiaro, F.; Ilari, A. Structural Insights into the Enzymes of the Trypanothione Pathway: Targets for Antileishmaniasis Drugs. *Future Med. Chem.* **2013**, *5*, 1861–1875. [[CrossRef](#)] [[PubMed](#)]
77. Souza, A.; Cardoso, F.; Martins, L.; Alves, C.; Silva, J.; Molfetta, F. Molecular Modelling Study of Heteroarylamide/Sulfonamide Compounds with Antitrypanosomal Activity. *J. Braz. Chem. Soc.* **2021**, *32*, 83–97. [[CrossRef](#)]
78. Vargas, J.A.R.; Lopez, A.G.; Piñol, M.C.; Froeyen, M. Molecular Docking Study on the Interaction between 2-Substituted-4,5-Difuryl Imidazoles with Different Protein Target for Antileishmanial Activity. *J. App. Pharm. Sci.* **2018**, *8*, 14–22. [[CrossRef](#)]
79. da Silva, A.D.; dos Santos, J.A.; Machado, P.A.; Alves, L.A.; Laque, L.C.; de Souza, V.C.; Coimbra, E.S.; Capriles, P.V.S.Z. Insights about Resveratrol Analogs against Trypanothione Reductase of *Leishmania braziliensis*: Molecular Modeling, Computational Docking and In Vitro Antileishmanial Studies. *J. Biomol. Struct. Dyn.* **2019**, *37*, 2960–2969. [[CrossRef](#)]
80. Feitosa, A.O.; Ferreira, F.J.N.; Brigido, H.P.C.; Bastos, M.L.C.; Carvalho, J.M.; Carneiro, A.S.; Dolabela, M.F.; Marinho, P.S.B.; Marinho, A.M.R. Study on Experimental Leishmanicidal Activity and In Silico of Cytochalasin B. *J. Braz. Chem. Soc.* **2019**, *30*, 592–596. [[CrossRef](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.